Adtalem (ATGE) Q4 Revenue Jumps 12%

Adtalem Global Education (ATGE) significantly surpassed Q4 FY2025 analyst estimates, reporting GAAP revenue of $457.1 million and adjusted EPS of $1.66, primarily driven by robust 10.2% total enrollment growth. Walden University led segment performance with a 15% enrollment increase and significant margin expansion, though Chamberlain University experienced margin compression despite strong enrollment, and the Medical and Veterinary segment neared capacity. Management issued FY2026 guidance projecting continued revenue growth to $1.90-$1.94 billion and adjusted EPS of $7.60-$7.90, indicating a more moderate top-line growth pace than the prior year while emphasizing ongoing strategic investments and disciplined capital allocation, including share repurchases and debt reduction.

Analysis

Adtalem Global Education (ATGE) reported a strong fourth quarter for fiscal 2025, exceeding analyst consensus for both revenue and adjusted earnings. Revenue of $457.1 million represented an 11.5% year-over-year increase and a 3.7% beat, while adjusted EPS of $1.66 grew 21.2% year-over-year, surpassing estimates by 8.5%. This outperformance was driven by a 10.2% surge in total student enrollment, with Walden University being the primary catalyst, posting a 15.0% enrollment increase and significant margin expansion attributed to the deployment of predictive analytics. Conversely, while Chamberlain University also saw robust enrollment growth of 5.8% and a 10.3% revenue increase, its adjusted operating margin contracted from 24.2% to 19.4% due to strategic investments. The Medical and Veterinary segment operated near capacity, limiting its enrollment growth to 1.0%, though its adjusted EBITDA still improved 21.7%. The company demonstrated strong financial discipline, generating $283.4 million in free cash flow, reducing net leverage to 0.8x, and executing $211 million in share repurchases. FY2026 guidance projects continued growth, with revenue forecasted at $1.90-$1.94 billion and adjusted EPS at $7.60-$7.90, implying top-line growth moderation but strong bottom-line expansion of 14.0% to 18.5%, signaling confidence in operating leverage.

Key Decisions for Investors

• Investors should note the strong FY2026 EPS growth guidance, which implies significant operating leverage, but must factor in the guided moderation in top-line growth against tough prior-year comparables.
• Closely monitor the operating margin at Chamberlain University to assess whether the current investments will yield a return to historical profitability levels, as this remains a drag on segment performance despite strong enrollment.
• Key risks to watch are the capacity constraints in the high-demand Medical and Veterinary segment, which could cap a key growth avenue, and any changes in the regulatory environment for federal student aid programs.